Resources

All Resources

Our resource hub to discover reports, policy papers and other forms of informative content

Filter by

Cost Drivers Report 2023

Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.

Learn more | View

Value of Medicines in Canada

This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.

Learn more | View

Cost of A Private Drug Plan Claim

IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.

Learn more | View

Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?

Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.

Learn more | View

Clinical Trials in Canada

The innovative pharmaceutical industry has sponsored over two-thirds of clinical trials initiated in Canada in the last 5 years and contributed over $15 billion to the Canadian economy annually.

Learn more | View

Innovative Access Arrangements and Managed Entry

A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs.

Learn more | View

Innovative Agreements Framework

Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.

Learn more | View

2022 Code of Ethical Practices

Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.

Learn more | View

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.